A Phase 1, Dose-Escalating, Multi-Center, Study of iSONEP (Sonepcizumab [LT1009]) Administered as an Intravitreal Injection to Subjects With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Latest Information Update: 12 Jan 2015
At a glance
- Drugs Sonepcizumab (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Adverse reactions
- Sponsors Lpath
- 04 Dec 2013 New trial record